文献速递妇科

接受根治性放化疗联合MRI引导近距离放疗的宫颈癌患者报告性健康结局

Patient-reported sexual health outcomes of cervical cancer patients treated with definitive chemoradiation and MRI-guided brachytherapy.
PubMed 文献 · Gynecol Oncol · 2024-08-27

本研究为前瞻性横断面研究,纳入2018年8月至2022年4月期间73例接受根治性放化疗的IB-IVA期宫颈癌患者,评估患者报告性健康结局与肿瘤医生评估的阴道毒性(VT)的相关性。结果显示性功能障碍、性困扰、严重更年期症状、焦虑和抑郁报告率分别为86.3%、54.5%、36.2%、46.6%和24.7%,2级及以上VT为27.4%,患者报告结局与VT无显著关联;多变量分析显示无伴侣状态、使用激素替代治疗及ICRU-RV剂量>65Gy与较差的性健康相关(p<0.005)。

要点

  • 宫颈癌患者自报性困扰、性功能障碍和更年期症状发生率较高。
  • 肿瘤医生评估的阴道毒性与患者报告结局之间无显著关联。
  • 无伴侣状态、激素替代治疗使用及ICRU-RV剂量>65Gy与较差的性健康相关(p<0.005)。

核心结论

  • 宫颈癌患者自报性困扰、性功能障碍和更年期症状发生率较高,肿瘤医生评估的VT与PROs不一致,凸显评估患者体验的重要性;作者认为可考虑积极治疗更年期症状并关注阴道放疗剂量。

研究设计与样本

  • 前瞻性横断面研究,纳入2018年8月至2022年4月期间73例接受根治性放化疗的IB-IVA期宫颈癌患者。

主要发现

  • 性功能障碍(FSFI评分≤26)、性困扰(FSDS-R≥11)、严重更年期症状(MRS≥17)、焦虑(HAD-焦虑>7)和抑郁(HAD-抑郁>7)的报告率分别为86.3%、54.5%、36.2%、46.6%和24.7%。
  • 2级及以上阴道毒性(VT)报告率为27.4%。
  • 患者报告结局(PROs)与VT之间未发现显著关联。
  • 多变量分析显示,无伴侣状态、使用激素替代治疗及ICRU-RV剂量>65Gy与较差的性健康相关(p<0.005)。

关键数值与推荐

  • 性功能障碍定义为FSFI评分≤26,性困扰定义为FSDS-R≥11,严重更年期症状定义为MRS≥17,焦虑定义为HAD-焦虑>7,抑郁定义为HAD-抑郁>7。
  • 阴道毒性采用CTCAE v4.0评估。
  • 多变量分析中无伴侣状态、激素替代治疗使用及ICRU-RV>65Gy与较差的性健康相关(p<0.005)。

临床怎么用

  • 作者认为可考虑积极治疗更年期症状并关注阴道放疗剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sexual health is an important survivorship issue in cervical cancer. We assessed patient-reported sexual health outcomes and correlations with oncologist-assessed vaginal toxicity (VT). METHODS: This was a prospective, cross-sectional study of stage IB-IVA cervical cancer patients treated with definitive chemoradiation, who completed a socio-demographic questionnaire and the following patient-reported-outcomes (PROs): Female Sexual Function Index (FSFI), Female Sexual Distress Scale-Revised (FSDS-R), Menopause Rating Scale (MRS), Hospital Anxiety and Depression Scale (HADS). VT was assessed using the CTCAE v4.0. Sociodemographic, clinical data, PROs and VT were summarized using descriptive statistics; correlations were evaluated using linear regression analyses. RESULTS: Between August 2018 and April 2022, 73 patients were analyzed. Median age was 49 (range 25-81), 57.5% had vaginal involvement at diagnosis and 76.9% were partnered. Sexual dysfunction (FSFI score ≤ 26), sexual distress (FSDS-R ≥ 11), severe menopausal symptoms (MRS ≥ 17), anxiety (HAD-Anxiety >7) and depression (HAS-Depression >7) were reported in 86.3%, 54.5%, 36.2%, 46.6% and 24.7%, respectively. Grade 2+ VT was reported in 27.4%. No significant associations were found between PROs and VT. On multivariable analysis, non-partnered status, use of hormone replacement therapy, and International Commission on Radiation Units and Measurements - rectovaginal dose (ICRU-RV) >65Gy were associated with worse sexual health (p < 0.005). CONCLUSION: Cervical cancer patients self-report high rates of sexual distress, dysfunction and menopause symptoms. Discordance between oncologist-assessed VT and PROs highlights the importance of evaluating the patient's experience. Proactive treatment of menopausal symptoms and attention to radiotherapy doses to the vagina should be considered.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chuk E, Conway JL, Hanuschak J, et al. Patient-reported sexual health outcomes of cervical cancer patients treated with definitive chemoradiation and MRI-guided brachytherapy. Gynecol Oncol. 2024. PMID: 39197414. doi:10.1016/j.ygyno.2024.08.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。